Khavinson bioregulators — 20 compounds explained.
A Russian gerontology research program spanning five decades produced more than twenty ultra-short peptides, each proposed to act on a specific organ. Here is the history, the theory, an honest look at the evidence, and an index to every one of the 20 compounds PeptideCompare now tracks.
- Khavinson bioregulators are ultra-short peptides (2–4 amino acids) from a five-decade Russian gerontology program.
- Each is proposed to act on a specific organ or tissue — pineal, thymus, vascular, and more.
- The theory is organ-specific gene regulation; the human evidence base is limited and largely from one research group.
- PeptideCompare tracks more than 20 of these compounds with prices and supplier data.
Who was Vladimir Khavinson?
Vladimir Khavinson is a Russian gerontologist who, alongside colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, spent decades developing and cataloguing short peptide sequences extracted from or modelled on specific animal organ tissues. The underlying idea: as organs age, the natural peptide signals that keep their cells properly regulated decline — and reintroducing a tissue-matched peptide might restore some of that regulatory signalling.
This research program produced two recognisable compounds PeptideCompare already tracked before this update — Epitalon (pineal gland) and Thymalin (thymus) — plus Vilon, Cortagen and Crystagen. With this update we've added the remaining 20 compounds from the same research family, completing the picture.
The theory: tissue-specific gene regulation
The proposed mechanism is distinct from how most peptides PeptideCompare tracks work. Compounds like BPC-157 or Ipamorelin bind a specific receptor to trigger a cascade. Khavinson's bioregulators are proposed instead to interact directly with chromatin or gene-expression machinery inside the cell nucleus, nudging a tissue's own genes back toward a more youthful expression pattern — without acting through a classical hormone receptor at all.
It's a mechanistically unusual claim, particularly for sequences as short as two or three amino acids (Thymagen is just Glu-Trp; Vesugen is Lys-Glu-Asp). Most established peptide hormones that influence gene expression do so indirectly, through receptor-triggered signalling cascades — not by interacting with DNA-regulatory machinery directly at such a small size. That doesn't make the claim impossible, but it does mean the burden of independent proof is higher than for a conventional receptor-agonist peptide.
Two distinct types, often confused
A single defined sequence of 2-4 amino acids, manufactured synthetically. Identity can be verified against a known formula — closer in principle to a conventional research peptide.
Extracted from animal organ tissue as a mixed complex (a "cytomedin") rather than one defined molecule. Harder to verify by formula — identity and consistency depend entirely on the supplier's COA.
Vendor marketing frequently blurs this distinction, presenting both types under the same "bioregulator" umbrella. It matters for sourcing: a natural complex without a single molecular formula needs a more rigorous COA — there's no simple lab test that confirms "this is definitely Ovagen" the way mass spectrometry confirms a synthetic peptide's exact sequence.
What the evidence actually shows
Nearly all published research on this entire compound family originates from the same Russian and Eastern European research lineage — largely the originating institute and closely affiliated groups. That doesn't automatically make the findings wrong, but it does mean independent replication outside that lineage is minimal to non-existent for most of these 20 compounds as of mid-2026. Western peer-reviewed journals have published very little on most of them individually.
Epitalon is the exception worth naming directly: it has the most outside-the-lineage research attention of any compound in this family, mainly around telomerase activity and animal lifespan studies — which is precisely why PeptideCompare already tracked it before this batch. The other 20 sit on a spectrum from "reasonably documented animal data" (Bronchogen, Cardiogen, Vesugen) to "sparse, almost entirely primary-source" (Bolamin, P21-adjacent organ bioregulators). Our individual guide for each compound states plainly where it falls on that spectrum.
All 20 compounds, by organ system
Each links to its full PeptideCompare research guide — mechanism, available evidence, EU legal status and sourcing notes. Tags mark whether a compound is a defined synthetic short peptide or a tissue-derived natural complex.
EU legal status
None of these 20 compounds are approved as medicines anywhere in the EU. They occupy the same general "unscheduled research chemical" position as most peptides PeptideCompare tracks: not specifically prohibited by name in most member states, but also not legal for human use, sale as a medicine, or marketing with therapeutic claims. See our EU legal guide for the country-by-country framework that applies to this entire category.
A practical note specific to this compound family: because several of the 20 are natural tissue-derived complexes rather than synthetic molecules, customs and import treatment can occasionally differ from synthetic research peptides in some jurisdictions. If in doubt, our EU customs guide covers the general principles.
Sourcing and quality — what to check
Only a small number of specialist EU vendors carry this compound family at all, and depth of testing varies more than for mainstream research peptides. For the synthetic short peptides (Cartalax, Sigumir, Thymagen and similar), the same COA standard applies as to any peptide: a batch-specific certificate from a named third-party lab confirming identity and purity.
For the natural peptide complexes (Endoluten, Ovagen, Chitomur, Pielotax, Prostamax, Suprefort, Taxorest, Bolamin, Vesilut), there's no single molecular formula a lab can simply confirm — verification depends much more heavily on supplier transparency and sourcing documentation than on a standard purity assay. Treat marketing claims for this sub-group with proportionately more scepticism, and see our COA guide and supplier vetting guide before ordering.